Skip to main content
. 2019 Aug 19;34(1):224–233. doi: 10.1038/s41375-019-0539-0

Fig. 5.

Fig. 5

PFS by treatment group in frail patients (a) and nonfrail patients (b), and OS by treatment group in frail patients (c) and nonfrail patients (d) aP values compare with MPT. PFS Progression-Free Survival, OS Overall Survival, MPT Melphalan + Prednisone + Thalidomide